A Phase II Study of AP23573, an mTOR Inhibitor, in Patients With Relapsed or Refractory Hematologic Malignancies
Sponsor study identifier
Secondary identifiers
interventional
57
1 country
8
Study Start
June 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2006
Actual (reported)Study Completion
June 2006
Actual (reported)The purpose of this phase II study is to assess the efficacy of AP23573 in patients with specified relapsed or refractory hematological malignancies.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2006
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 2004
Date type not reportedThis date has not been verified as actual or estimated.
June 24, 2004
Actual (reported)June 28, 2004
Actual (reported)June 2006
Actual (reported)June 2006
Actual (reported)To assess efficacy of AP23573 in patients with relapsed or refractory hematologic malignancies.
Duration of study
Evaluating time to progression, progression-free survival, duration of response and safety
Duration of study
AP23573 12.5 mg IV as monotherapy once daily for 5 days, every 2 weeks
AP23573 12.5 mg IV as monotherapy once daily for 5 days, every 2 weeks
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
University of Chicago Hospitals, Section of Hematology/Oncology
Chicago, Illinois, 60637, United States
Washington University School of Medicine, Siteman Cancer Center, 4921 Parkview Place
St Louis, Missouri, 63110, United States
The Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
New York Presbyterian Hospital, Weill College of Cornell University
New York, New York, 10021, United States
Morris Cancer Center - Duke University Medical Center, Adult Bone Marrow Transplant Clinic
Durham, North Carolina, 27705, United States
Gabrail Cancer Center
Canton, Ohio, 44718, United States
Rizzieri DA, Feldman E, Dipersio JF, Gabrail N, Stock W, Strair R, Rivera VM, Albitar M, Bedrosian CL, Giles FJ. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2008 May 1;14(9):2756-62. doi: 10.1158/1078-0432.CCR-07-1372.
Frank Haluska, M.D., Ph.D.
Ariad Pharmaceuticals
57 participants (actual enrollment reported by the registry).
First Submitted
June 24, 2004
First Posted
June 28, 2004
Study Start
June 2004
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to confirm eligibility.
Jeane's Hospital of TUHS
Philadelphia, Pennsylvania, 19111, United States
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Primary Completion
June 2006
Actual (reported)Study Completion
June 2006
Actual (reported)Last Updated
August 19, 2015
Record last verified: 2015-08
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: